Skip to main content Skip to main navigation menu Skip to site footer
Articles
Published: 2021-11-04

COVID-19 and Psoriasis: A Concise Systematic Review

UnB - Universidade de Brasília/University of Brasilia / School of Health Sciences, Brasilia, Distrito Federal, Brazil
Universidade de Rio Verde (UniRV), Goias, Brazil
Escola Superior em Ciências da Saúde (ESCS), Brasília, Distrito Federal, Brazil
Centro Universitário de Brasília (UniCEUB), Brasília, Distrito Federal, Brazil
Escola superior em ciências da saúde (ESCS), Brasília, Distrito Federal, Brazil
Universidade de Uberaba (UNIUBE), Minas Gerais, Brazil
Universidade Católica de Brasília (UCB), Distrito Federal, Brazil
Universidade Federal de Minas Gerais, Brazil
Centro Universitário de Brasília (UniCEUB), Brasília, Distrito Federal, Brazil
ABRAN - Associação Brasileira de Nutrologia /Brazilian Association of Nutrology, Catanduva/SP, Brazil
COVID-19 SARS-CoV-2 Psoriasis Dermatological diseases Hyperinflammation Meta-inflammation

Abstract

Introduction: The effects on human health caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) lead to hyperinflammation processes, which can lead to meta-inflammation. This process can aggravate skin diseases, especially psoriasis. This is a chronic inflammatory skin disease associated with significant morbidity. This problem affects about 2-3% of people worldwide. Objective: to demonstrate, through a concise systematic review, the main considerations about the relationship between COVID-19 and psoriasis, showing the possible mechanisms for the worsening of this dermatological disease. Methods: The research was carried out from June 2021 to July 2021 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar, following the Systematic Review-PRISMA rules. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results: Psoriasis is a common chronic inflammatory skin disease and is autoimmune. Patients with COVID-19 may have features of hyper inflammation and even meta-inflammation. The triggering or exacerbating factor of psoriasis may be medications and, in addition, patients with COVID-19 may have psoriasis exacerbation. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease. It is envisioned that the use of azithromycin in cases of COVID 19 with pre-existing psoriasis can alleviate psoriatic lesions. Conclusion: The COVID 19 pandemic had a direct impact on dermatological diseases, especially psoriasis. Difficulty in accessing health care services and the stress load caused exacerbations in psoriasis cases. Studies recommend avoiding classic immunosuppressive agents such as methotrexate, cyclosporine, and TNF alpha inhibitors. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease.

References

  1. WHO. Naming the coronavirus disease (covid-19) and the virus that causes it. 2020. Available in:www.int/emergencies/diseases/novel-coronavirus-/technical-guidance/namingthecoronavirus-disease--and-the-virus-that-causes-it.
  2. Kutlu O, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic? Dermatol Ther. 2020:e13383.
  3. Ye C, Cai S, Shen G, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis. 2020.
  4. Kizilyel O, Akdeniz N, Metin MS, Elmas OF. Investigation of oxidant and antioxidant levels in patients with psoriasis. Turk J Med Sci. 2019;49(4):1085-1088.
  5. Gran F, Kerstan A, Serfling E, Goebeler M, Muhammad K. Current Developments in the Immunology of Psoriasis. Yale J Biol Med. 2020;93(1):97-110.
  6. Atzori L, Mugheddu C, Addis G, et al. Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in sardinia (Italy). J Eur Acad Dermatol Venereol. 2020.
  7. Elmas ÖF, Demirbaş A, Kutlu Ö, Bağcıer F, Metin MS, Özyurt K, Akdeniz N, Atasoy M, Türsen Ü, Lotti T. Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol Ther. 2020 Nov;33(6):e13858. doi: 10.1111/dth.13858. Epub 2020 Jul 9. PMID: 32686245; PMCID: PMC7323009.
  8. Amerio P, Prignano F, Giuliani F, Gualdi G. COVID-19 and psoriasis: Should we fear for patients treated with biologics? Dermatol Ther. 2020 Jul;33(4):e13434. doi: 10.1111/dth.13434. Epub 2020 May 5. PMID: 32314483; PMCID: PMC7235531.
  9. Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, Mozafarpoor S, Almasi S, Goodarzi A. Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review. Dermatol Ther. 2020 Nov;33(6):e13986. doi: 10.1111/dth.13986. Epub 2020 Aug 6. PMID: 32639077; PMCID: PMC7362033.
  10. Kanda N, Hoashi T, Saeki H. Nutrition and Psoriasis. Int J Mol Sci. 2020 Jul 29;21(15):5405. doi: 10.3390/ijms21155405. PMID: 32751360; PMCID: PMC7432353.
  11. Madden SK, Flanagan KL, Jones G. How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis. Clin Nutr. 2020 Apr;39(4):1026-1040. doi: 10.1016/j.clnu.2019.05.006. Epub 2019 May 11. PMID: 31155371.
  12. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n71.
  13. H Balshem H, Grade guidelines: 3 ratng the quality of evidence. Journal of Clinical Epidemiology, Maryland Heights, 64 (4) (2011) 401-406.
  14. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
  15. Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020 Sep;33(5):e13687. doi: 10.1111/dth.13687. Epub 2020 Jun 19. PMID: 32458536; PMCID: PMC7283778.
  16. Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H. Covid-19 and exacerbation of psoriasis. Dermatol Ther. 2020 Jul;33(4):e13632. doi: 10.1111/dth.13632. Epub 2020 Jun 2. PMID: 32436303; PMCID: PMC7280710.
  17. Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J Dermatolog Treat. 2020 Jul 6:1-5. doi: 10.1080/09546634.2020.1789051. Epub ahead of print. PMID: 32598204.
  18. Kuang Y, Shen M, Wang Q, et al. Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: A web-based survey. J Am Acad Dermatol. 2020.
  19. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020.
  20. Kutlu O, Metin A. Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol Ther. 2020:e13509.
  21. Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H. Covid-19 and Exacerbation of Psoriasis. Dermatol Ther. 2020.
  22. Kutlu O, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic? Dermatol Ther. 2020:e13383.
  23. Said A, Bock S, Lajqi T, Muller G, Weindl G. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014;193(12):6135-6143.
  24. Saxena VN, Dogra J. Long-term oral azithromycin in chronic plaque psoriasis: a controlled trial. Eur J Dermatol. 2010;20(3):329-333.
  25. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021 May;84(5):1254-1268. doi: 10.1016/j.jaad.2020.12.058.
  26. Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CEM, Barker JN, Smith CH; PsoProtect study group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021 Jan;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007.

How to Cite

Rocha, M. S., Aquino, L. L. de, Rodrigues, Ágda T. da S., Oliveira, C. P. de, Lazo, L. M. M., Salviano, J. L., Valadão, L. V., Batista, M. M., Lopes, V. B., & Ribas Filho, D. (2021). COVID-19 and Psoriasis: A Concise Systematic Review. MedNEXT Journal of Medical and Health Sciences, 2(4). https://doi.org/10.54448/mdnt2143